Breaking News

Mundipharma Acquires Rights to Orexo’s Zubsolv

To commercialize the opioid dependence drug in Australia and New Zealand

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Orexo AB has signed an agreement granting Mundipharma Pty Ltd. (Mundipharma Australia) the exclusive rights to commercialize Orexo’s lead product, Zubsolv, for the treatment of opioid dependence, in Australia and New Zealand. Mundipharma Australia supported Orexo in obtaining marketing authorization for Zubsolv in Australia. Orexo will now be responsible for product supply and Mundipharma Australia will take responsibility for commercialization of Zubsolv in Australia and New Zealand. Ore...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters